Molbio Diagnostics Set for Today’s Stock Market Debut; Investors Urged to Review GMP Before Listing

Molbio Diagnostics is poised for a significant stock market debut on August 17, following a strong initial public offering (IPO) that closed with an impressive subscription rate of 70.26 times. The grey market premium (GMP) currently stands at 15%, pointing to a positive market sentiment, albeit slightly below the 19% observed during the allotment period. The IPO, valued at Rs 939.70 crore, features a pricing of Rs 807 per share, consisting of fresh shares worth Rs 200 crore and an offer for sale amounting to Rs 739.70 crore. The overwhelming response from investors, particularly qualified institutional buyers (QIBs) who subscribed 186.39 times, underscores strong market confidence in the company’s prospects.

Molbio is strategically allocating the IPO proceeds—approximately Rs 205.93 crore—to bolster its infrastructure, research, and manufacturing capabilities. Key investments include Rs 125.12 crore allocated for developing a new research and development facility, along with Rs 80.81 crore directed toward enhancing manufacturing capabilities in Goa and Visakhapatnam. This systematic expansion is vital for maintaining Molbio’s competitive edge, particularly in the rapidly evolving field of molecular diagnostics, where the company offers over 43 diagnostic assays through its proprietary Truenat platform.

Financially, Molbio has displayed robust growth, with total income rising 42% year-on-year to Rs 1,455 crore in FY26, compared to Rs 1,027 crore in FY25. Profit after tax also saw significant growth, increasing 18% to Rs 164 crore from Rs 138.58 crore. These financial metrics paint a promising picture of the company’s ability to capitalize on the growing demand for rapid diagnostic solutions amid an increasing focus on healthcare. Investors will be closely monitoring the debut on the BSE and NSE, as well as the sustained performance of Molbio Diagnostics in the coming quarters, amidst a broader trend of innovation in healthcare diagnostics.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)